Indrayani Biotech FY26 results: auditor flags qualified opinion
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indrayani Biotech reported FY26 consolidated revenue of Rs 13,783 lakhs (up 5.8% YoY) and a turnaround PAT of Rs 216 lakhs against a prior year loss of Rs 611 lakhs. Consolidated EPS rose to Rs 0.48 from negative Rs 1.35. Standalone revenue fell about 42% to Rs 2,190 lakhs and standalone PAT dropped 52% to Rs 70 lakhs. Statutory auditor Venkatesh & Co issued a qualified opinion on both reports, flagging unconfirmed loan, receivable, and trade creditor balances, plus two subsidiaries using Indian GAAP instead of IND AS.
Auditor's qualified opinion and 42% standalone revenue decline raise concerns, though consolidated numbers show a sharp turnaround.